当这些患者接受靶向治疗作为CLL的初始治疗时,按TP53异常状态或10%VAF临界值划分的亚组之间OS无差异。 范磊教授点评 TP53异常(突变或/和缺失)是慢性淋巴细胞白血病(CLL)的重要预后不良因素,以往甚至称为超高危CLL,这类患者占初治CLL比例...
体细胞突变(somatic mutation):大部分肿瘤细胞发生的是体细胞突变,突变局限于病变组织或系统中,不会遗传给子女,例如发生在造血系统的体细胞突变,在其它系统中不会被检出。体细胞突变比例一般<50%,但若伴随等位基因缺失(如伴随17p-),则突变比例>50%。 嵌合体突变(mosaic mutation):在胚胎发育过程中发生的突变,导致...
TP53 Mutations and Survival in SquamousCell Carcinoma of the Head and Neck, NEJM, 2007 Prognostic Impact of TP53 Mutations in Metastatic Nonsquamous Non–small-cell Lung Cancer, Clinical Lung Cancer, 2024 TP53 Mutation and Survival in Chronic Lymphocytic Leukemia, Journal of Clinical Oncology, 2010 ...
Genomic aberrations and gene mutations are among the strongest prognostic factors in CLL. In particular, patients with mutated TP53 (TP53mut) and/or deleted chromosome 17p (del17p) have a worse response to therapy and significantly shorter progression-free survival (PFS) and overall survival (OS...
这种p53介导的、对BH3模拟药物反应的机制尚不清楚,但最近的分析表明,在venetoclax治疗后,TP53缺陷的CLL或AML患者的预后比TP53充足的白血病患者差。理想情况下,该疗法将与能够独立于p53、且有效杀死恶性细胞的药物联合使用。 近日,来自澳大利亚...
Twelve CLL patients at diagnosis were included in this study. All except one patient showed the TP53 gene deletion in Fluorescence in situ hybridization experiments. Patients were investigated forTP53mutation by Sanger and by MinION sequencing. Analysis by Sanger was performed according with the IARC ...
(B) TP53 mutations in 141 patients with CLL, in order according the highest VAF. Black, highest mutation VAF; white, cumulative mutation VAF. Compared with patients bearing TP53-wt, the subgroup with high-burden TP53 mutations was significantly associated with unmutated immunoglobulin genes (IGHV;...
B-ALL patients with TP53 gene mutation should undergo allo-HSCT as soon as possible after CAR-T cell therapy has cleared the MRD after recurrence. B-ALL patients with TP53 gene mutation still have a higher recurrence rate after allo-HSCT, and the infusion of donor-derived CAR-T cells can...
In chronic lymphocytic leukemia (CLL), the worst prognosis is associated with TP53 defects with the affected patients being potentially directed to alternative treatment. Therapy administration was shown to drive the selection of new TP53 mutations in CL
Panelists review recent ESMO guideline updates for the frontline management of patients with CLL and a TP53 or del(17p) mutation. This is a modal window. This video is either unavailable or not supported in this browser Error Code: MEDIA_ERR_SRC_NOT_S...